The role of the pharmacist in the care of patients with cancer is evolving. Pharmacists can help optimize treatment outcomes for each patient through use of patient-specific and disease-specific strategies.
In her presentation, “Clinical Issues in Oncology Management,” Rowena N. Schwartz, PharmD, BCOP, senior director of Clinical Content Services at McKesson Specialty Health, outlined ways in which healthcare providers can help optimize the care of oncology patients. She also noted special considerations for the treatment of patients with breast cancer, cancer treatment—induced bone loss, and myeloma.
A major challenge associated with cancer drug therapies is accounting for and managing the treatment of comorbidities. The treatment of one condition can affect the therapy for another, effectively changing the clinical situation, Dr Schwartz explained. In order to manage drug-drug interactions and drug-food interactions, oncology pharmacists should screen patients for contraindications at each visit, taking into consideration the potential for unrecognized or under-reported drug interactions. Patients should also be educated about potential conflicts in treatment regimens.
In the case of oral oncolytics, pharmacists can be instrumental in the management of dose modifications and can help identify treatment-related dose toxicities in their patients. In addition, pharmacists in the oncology setting can play an important role in helping patients gain access to treatments and influencing them to remain adherent.
Cancer survivorship can be defined as the time of diagnosis through the balance of the patient’s life, as the period following primary treatment, or simply as the existence of an individual who has been diagnosed with cancer and is still living. Despite the incongruity of definitions, cancer survivorship is a distinct phase of cancer care for which “awareness and improvement in quality is needed,” according to Dr Schwartz. Providers should be aware that survivors may experience diminished quality of life as a result of physiological sequelae, psychological distress, and social life disruption.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More